Glucocorticoid-induced osteoporosis in premenopausal women: management for the rheumatologist.
Journal
Current opinion in rheumatology
ISSN: 1531-6963
Titre abrégé: Curr Opin Rheumatol
Pays: United States
ID NLM: 9000851
Informations de publication
Date de publication:
01 05 2023
01 05 2023
Historique:
medline:
3
4
2023
pubmed:
22
3
2023
entrez:
21
3
2023
Statut:
ppublish
Résumé
This review seeks to summarize the literature relevant to the treatment of glucocorticoid-induced osteoporosis in premenopausal women; an issue commonly encountered by rheumatologists and yet lacking good clinical practice guidelines. Although most of the relevant literature on osteoporosis includes postmenopausal women only, data from both randomized controlled trials and case reports suggest bisphosphonates can be an effective and well tolerated treatment for premenopausal patients. Data for other medications to treat premenopausal osteoporosis is less robust. The use of bisphosphonates in young women may be safer than initially thought and should likely be used for the treatment of glucocorticoid-induced osteoporosis in rheumatology clinics. Further research is needed to continue to understand long-term risk.
Identifiants
pubmed: 36943706
doi: 10.1097/BOR.0000000000000934
pii: 00002281-202305000-00005
doi:
Substances chimiques
Glucocorticoids
0
Diphosphonates
0
Types de publication
Review
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
161-169Informations de copyright
Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.
Références
Langdahl BL. Osteoporosis in premenopausal women. Curr Opin Rheumatol 2017; 29:410–415.
Canalis E. Mechanisms of glucocorticoid-induced osteoporosis. Curr Opin Rheumatol 2003; 15:454–457.
Zhu L, Zhang J, Wang J, et al. Uncoupled bone remodeling is characteristic of bone damage in premenopausal women with new-onset systemic lupus erythematosus. Lupus 2021; 30:1116–1123.
Pepe J, Body JJ, Hadji P, et al. Osteoporosis in premenopausal women: a clinical narrative review by the ECTS and the IOF. J Clin Endocrinol Metab 2020; 105:2487–2506.
Cohen A, Shane E. Treatment of premenopausal women with low bone mineral. Curr Osteoporos Rep 2008; 6:39–46.
Bachrach LK, Hastie T, Wang MC, et al. Bone mineral acquisition in healthy Asian, Hispanic, black, and Caucasian youth: a longitudinal study. J Clin Endocrinol Metab 1999; 84:4702–4712.
Lauder TD, Dixit S, Pezzin LE, et al. The relation between stress fractures and bone mineral density: evidence from active-duty army women. Arch Phys Med Rehabil 2000; 81:73–79.
Wigderowitz CA, Cunningham T, Rowley DI, et al. Peripheral bone mineral density in patients with distal radial fractures. J Bone Joint Surg Br 2003; 85:423–425.
Hung LK, Wu HT, Leung PC, Qin L. Low BMD is a risk factor for low-energy Colles’ fractures in women before and after menopause. Clin Orthop Relat Res 2005; 435:219–225.
Wu FMB, Hrne A, Ames R, et al. Fractures between the ages of 20 and 50 years increase women's risk of subsequent fractures. Arch Intern Med 2002; 162:33–36.
Rheumatology ACo 2022 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis: Guideline Summary. 2022.
Herath M, Langdahl B, Ebeling PR, Milat F. Challenges in the diagnosis and management of glucocorticoid-induced osteoporosis in younger and older adults. Clin Endocrinol (Oxf) 2022; 96:460-.
Nzeusseu Toukap ADG, Devogelaer J-P, Houssiau FA. Oral pamidronate prevents high-dose glucocorticoid-induced lumbar spine bone loss in premenopausal connective tissue (mainly lupus) disease. Lupus 2005; 14:517–520.
Nakayamada SOY, Saito K, Tanaka Y. Etidronate prevents high dose glucocorticoid induced bone loss in premenopausal individuals with systemic autoimmune diseases. J Rheumatol 2004; 31:163–166.
de Nijs RNJ, Jacobs JWG, Lems WF, et al. STOP Investigators. Alendronate or alfacalcidol in glucocorticoid induced osteoporosis. N Engl J Med 2006; (355):675–684.
Roux C, Reid DM, Devogelaer JP, et al. Post hoc analysis of a single IV infusion of zoledronic acid versus daily oral risedronate on lumbar spine bone mineral density in different subgroups with glucocorticoid-induced osteoporosis. Osteoporos Int 2012; 23:1083–1090.
Saag KG, Shane E, Boonen S, et al. Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Engl J Med 2007; 357:2028–2039.
Saag KG, Zanchetta JR, Devogelaer JP, et al. Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: thirty-six-month results of a randomized, double-blind, controlled trial. Arthritis Rheum 2009; 60:3346–3355.
Kung AWC, Chan TM, Lau CS, et al. Osteopenia in young hypogonadal women with systemic lupus erythematosus receiving chronic steroid therapy: a randomized controlled trial comparing calcitriol and hormonal replacement therapy. Rheumatology (Oxford) 1999; 38:1239–1244.
Ioannis SP, Aikaterini CL, George K, et al. The use of bisphosphonates in women prior to or during pregnancy and lactation. Hormones 2011; 10:280–291.
Patlas NGG, Yaffe P, Pinto T, et al. Transplacental effects of bisphosphonates on fetal skeletal ossification and mineralization in rats. Teratology 1999; 60:68–73.
Djokanovic N, Klieger-Grossmann C, Koren G. Does treatment with bisphosphonates endanger the human pregnancy? J Obstet Gynaecol Can 2008; 30:1146–1148.
Chan B, Zacharin M. Maternal and infant outcome after pamidronate treatment of polyostotic fibrous dysplasia and osteogenesis imperfecta before conception: a report of four cases. J Clin Endocrinol Metab 2006; 91:2017–2020.
Ornoy A, Wajnberg R, Diav-Citrin O. The outcome of pregnancy following prepregnancy or early pregnancy alendronate treatment. Reprod Toxicol 2006; 22:578–579.
Sokal A, Elefant E, Leturcq T, et al. Pregnancy and newborn outcomes after exposure to bisphosphonates: a case-control study. Osteoporos Int 2019; 30:221–229.
Losada I, Sartori L, Di Gianantonio E, et al. Bisphosphonates in patients with autoimmune rheumatic diseases: can they be used in women of childbearing age? Autoimmun Rev 2010; 9:547–552.
Forteo [package insert]. Indianapolis, IN: Eli Lilly and Company; 2021.
Agarwal S, Shane E, Lang T, et al. Spine volumetric BMD and strength in premenopausal idiopathic osteoporosis: effect of teriparatide followed by denosumab. J Clin Endocrinol Metab 2022; 107:e2690–e2701.
Black DM, Bilezikian JP, Ensrud KE, et al. PaTH Study Investigators. One year of alendronate after one year of parathyroid hormone for osteoporosis. N Engl J Med 2005; 353:555–565.
Cerit ET, Cerit M. A case of pregnancy and lactation associated osteoporosis in the third pregnancy; robust response to teriparatide despite delayed administration. Bone Rep 2020; 13:100706.
Hardcastle SA. Pregnancy and lactation associated osteoporosis. Calcif Tissue Int 2022; 110:531–545.
Conradie M, de Villiers T. Premenopausal osteoporosis. Climacteric 2022; 25:73–80.
Bussiere JL, Pyrah I, Boyce R, et al. Reproductive toxicity of denosumab in cynomolgus monkeys. Reprod Toxicol 2013; 42:27–40.
Anastasilakis AD, Polyzos SA, Makras P, et al. Clinical features of 24 patients with rebound-associated vertebral fractures after denosumab discontinuation: systematic review and additional cases. J Bone Miner Res 2017; 32:1291–1296.
Tsourdi E, Langdahl B, Cohen-Solal M, et al. Discontinuation of denosumab therapy for osteoporosis: a systematic review and position statement by ECTS. Bone 2017; 105:11–17.
Symonds C, Kline G. Warning of an increased risk of vertebral fracture after stopping denosumab. CMAJ 2018; 190:E485–E486.
Stumpf U, Kraus M, Hadji P. Influence of denosumab on bone mineral density in a severe case of pregnancy-associated osteoporosis. Osteoporos Int 2021; 32:2383–2387.
Ott SM. Long-term safety of bisphosphonates. J Clin Endocrinol Metab 2005; 90:1897–1899.
Schreiber K, Frishman M, Russell MD, et al. British Society for Rheumatology guideline on prescribing drugs in pregnancy and breastfeeding: comorbidity medications used in rheumatology practice. Rheumatology (Oxford) 2022; keac552.
Machairiotis N, Ntali G, Kouroutou P, et al. Clinical evidence of the effect of bisphosphonates on pregnancy and the infant. Horm Mol Biol Clin Investig 2019; 40:1–7.
Pereira RMR, de Carvalho JF, Paula AP, et al. Guidelines for the prevention and treatment of glucocorticoid induced osteoporosis. Rev Brs Rheumatol 2012; 52:580–593.
Bhalla AK. Management of osteoporosis in a premenopausal woman. Best Pract Res Clin Rheumatol 2010; 24:313–327.
Ward KD, Klesges RC. A meta-analysis of the effects of cigarette smoking on bone mineral density. Calcif Tissue Int 2001; 68:259–270.
Vondracek SF, Hansen LB, McDermott MT. Osteoporosis risk in premenopausal women. Pharmacotherapy 2009; 29:305–317.
Bacon L, Stern JS, Keim NL, Van Loan MD. Low bone mass in premenopausal chronic dieting obese women. Eur J Clin Nutr 2004; 58:966–971.
Martyn-St James M, Carroll S. Effects of different impact exercise modalities on bone mineral density in premenopausal women: a meta-analysis. J Bone Miner Metab 2010; 28:251–267.
Vainionpaa A, Korpelainen R, Leppaluoto J, Jamsa T. Effects of high-impact exercise on bone mineral density: a randomized controlled trial in premenopausal women. Osteoporos Int 2005; 16:191–197.
Zhao R, Zhao M, Zhang L. Efficiency of jumping exercise in improving bone mineral density among premenopausal women: a meta-analysis. Sports Med 2014; 44:1393–1402.
Black DM, Rosen CJ. Clinical practice postmenopausal osteoporosis. N Engl J Med 2016; 374:254–262.
Bischoff-Ferrari HA, Willett WC, Wong JB, et al. Fracture prevention with vitamin d supplementation: a meta-analysis of randomized controlled trials. JAMA 2005; 293:2257–2264.
American College of Obstetricians and Gynecologists. Committee Opinion 602: Depot medroxyprogesterone acetate and bone effects. Obstet Gynecol 2014; 123:1398–1402.
Quintino-Moro A, Zantut-Wittmann DE, Silva Dos Santos PN, et al. Changes in calcium metabolism and bone mineral density in new users of medroxyprogesterone acetate during the first year of use. Int J Gynaecol Obstet 2019; 147:319–325.
Xie J, Tong A, Kim SC. Patterns of bisphosphonates utilization in patients under age 45 in a large cohort of commercial insurance beneficiaries in the United States. PLoS One 2015; 10:e0115091.